Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medicis Pharmaceutical Corp    MRX

SummaryNewsCompany 
News SummaryMost relevantAll newsSector news 

Medicis Pharma Shares Fall on Q-Med Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2012 | 09:03pm CET
   By Anna Prior 
 

Q-Med Inc., a division of pharmaceutical company Galderma, has sued Medicis Pharmaceutical Corp. (>> Medicis Pharmaceutical Corp) over the contracts for several dermal filler products in connection with Medicis's planned merger with Valeant Pharmaceuticals International Inc. (>> Valeant Pharmaceuticals Intl Inc).

Medicis shares recently fell 3.3% to $41.91 on heavy volume as investors worried about the impact the lawsuit could have on the merger. The stock has risen 26% for the year, jumping 38% after Valeant announced a $44-a-share offer price.

In its quarterly filing, Medicis said Q-Med is alleging breach of obligation regarding its licensing and contracts for Restylane and Perlane, and it has the right to withhold consent to a change-of-control of Medicis that would result in a transfer to Valeant of the exclusive rights to market and sell the dermal filler products.

"We think their position is without merit," said Laurie Little, vice president of investor relations for Valeant. "We're going to go ahead and vigorously defend ourselves."

Medicis also said in the filing that the merger agreement doesn't require the consent of Q-Med, and Ms. Little added that at this point, Valeant is still moving forward with the transaction.

In September, Valeant agreed to buy Medicis for $2.6 billion, the latest in a string of acquisitions that have transformed the Canadian drug maker into a multibillion-dollar global company. Valeant focuses on branded pharmaceuticals, branded generics and over-the-counter products, and it specializes in neurology and dermatology.

Write to Anna Prior at anna.prior@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDICIS PHARMACEUTICAL COR
03/21 TIMELINE : Shakeup at Valeant as longtime CEO Pearson leaving
2015 From pilot to profit-maker, Valeant's pharmacy rose quickly
2012DJGarmin to Join S&P 500 Index, Replacing RR Donnelley
2012 MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Announces New Management A..
2012 MEDICIS PHARMACEUTICAL CORP : Valeant Pharmaceuticals Receives FTC Clearance For..
2012DJMedicis Pharma Shares Fall on Q-Med Lawsuit
2012 MEDICIS PHARMACEUTICAL CORP : Medicis Declares Cash Dividend
2012 MEDICIS PHARMACEUTICAL CORP : Law Office of Brodsky & Smith, LLC Announces Inves..
2012 MEDICIS PHARMACEUTICAL CORP : Faruqi & Faruqi, LLP Is Seeking More Cash For The ..
2012DJU.S. HOT STOCK FUTURES : Hot stocks to watch
More news
Sector news : Generic Pharmaceuticals
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Generic Pharmaceuticals
Advertisement
Sector and Competitors
1st jan.Capitalization (M$)
MEDICIS PHARMACEUTICAL..0
SUN PHARMACEUTICAL IND..-17.93%23 936
OTSUKA HOLDINGS CO LTD3.02%21 602
ONO PHARMACEUTICAL CO...-43.88%12 387
ASPEN PHARMACARE HOLDI..-10.45%9 020
SHANGHAI FOSUN PHARMAC..-1.11%8 021
More Results